Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors: David Marin et al
Purpose:
We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.
Purpose:
We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.
- Read more about Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors: David Marin et al
- Email this page
Chronic Myeloid Leukemia 2010:Where Are We Now and Where Can We Go? Jerald P. Radich
Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases, as well as molecular tools to monitor disease and characterize resistance. However, there are still unanswered questions regarding optimization of therapy, the utility of molecular monitoring, and the search (or need) of “cure” that bears thought. In this review, we will discuss these issues, as they provide a roadmap for what may lie ahead in the therapy of other hematologic malignancies, particular the other myeloproliferative syndromes, where specific genetic lesions, and targeted therapy, are now being realized.
Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases, as well as molecular tools to monitor disease and characterize resistance. However, there are still unanswered questions regarding optimization of therapy, the utility of molecular monitoring, and the search (or need) of “cure” that bears thought. In this review, we will discuss these issues, as they provide a roadmap for what may lie ahead in the therapy of other hematologic malignancies, particular the other myeloproliferative syndromes, where specific genetic lesions, and targeted therapy, are now being realized.
Poor response to second-line kinase inhibitors in CML patients with multiple low-level mutations, irrespective of their resistance profile
Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.
CML Support Group: Response to the Appeal Panel Judgement
CML Support Group: Response to the Appeal Panel judgement in favour of the NICE
decision not to recommend dasatinib as a second line treatment option for imatinib
resistant CML and in patients intolerant to imatinib, and including its use in blast
phase CML.
CML Support Group: Response to the Appeal Panel judgement in favour of the NICE
decision not to recommend dasatinib as a second line treatment option for imatinib
resistant CML and in patients intolerant to imatinib, and including its use in blast
phase CML.
NICE say NO to dasatinib and high dose IM. Full Guidance
Guidance: Patient version
Dasatinib, high-dose imatinib and nilotinib for chronic myeloid leukaemia:
This document is about when dasatinib, high-dose imatinib and
nilotinib should be used to treat people with chronic myeloid leukaemia
that has not responded to imatinib or who cannot tolerate imatinib in the
NHS in England and Wales. It explains guidance (advice) from NICE
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? Junia V. Melo1 and David M. Ross2
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley OncologySTAT Editorial Team. Nov 23 2010
CML—The Changing Landscape of Front-line Therapy:
Interview With Dr. Jane Apperley
CML—The Changing Landscape of Front-line Therapy:
Interview With Dr. Jane Apperley
2-year follow-up from a randomized phase 3 trial (DASISION)
Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
CMLSg's Campaigning Activity 2011
Given the imminent publication by NICE of their draft appraisal document for dasatinib, nilotinib and imatinib in 1st line use, I thought it a good idea to update you all on CMLSg's campaigning activities during the latter half of this year.
Given the imminent publication by NICE of their draft appraisal document for dasatinib, nilotinib and imatinib in 1st line use, I thought it a good idea to update you all on CMLSg's campaigning activities during the latter half of this year.
Possible cure for leukemia found by Penn State researchers
University of Pennsylvania (Penn State) researchers Sandeep Prahbu and Rober Paulson with interest in Leukaemia studied a compound called D12-PGJ3 derived from fish oil which targeted and killed CML stem cells in mice. It is hoped that this might lead to a cure for the disease as the CML stem cell remains active in most patients despite successful therapy with TK inhibitors.
University of Pennsylvania (Penn State) researchers Sandeep Prahbu and Rober Paulson with interest in Leukaemia studied a compound called D12-PGJ3 derived from fish oil which targeted and killed CML stem cells in mice. It is hoped that this might lead to a cure for the disease as the CML stem cell remains active in most patients despite successful therapy with TK inhibitors.